摘要
目的分析丁苯酞软胶囊联合多奈哌齐治疗对帕金森综合征患者临床效果、认知功能及日常生活能力的影响。方法选取2017年6月—2020年6月本院收治的帕金森综合征患者96例,根据不同治疗方式分为研究组(丁苯酞软胶囊联合多奈哌齐治疗)及对照组(仅予多奈哌齐治疗)各48例。比较2组治疗后临床疗效,治疗前后蒙特利尔认知评估量表(MoCA)评分、日常生活活动能力(ADL)评分、帕金森综合征评定量表(UPDRS)评分、简易精神状态检查量表(MMSE)评分和重组人帕金森病蛋白7(PARK7)、神经营养因子-3(NT-3)、C反应蛋白(CRP)水平,以及不良反应发生情况。结果研究组总有效率明显高于对照组(P<0.01)。治疗后,2组MoCA、ADL及MMSE评分较治疗前明显升高,UPDRS评分较治疗前明显下降,且以研究组尤甚,差异有统计学意义(P<0.05或P<0.01)。治疗后,2组NT-3、PARK7、CRP均显著改善,其中研究组改善尤为明显,差异有统计学意义(P<0.05或P<0.01)。研究组治疗后不良反应总发生率明显低于对照组(P<0.05)。结论帕金森综合征患者予丁苯酞软胶囊联合多奈哌齐治疗临床效果佳,并可改善患者认知功能及日常生活能力,且安全性高。
Objective To analyze effects of Butylphthalide Soft Capsule combined with Donepezil on clinical efficacy,cognitive function and activities of daily living in treatment of patients with Parkinson's syndrome.Methods A total of 96 patients with Parkinson's syndrome admitted during June 2017 and June 2020 were selected and divided into research group(Butylphthalide Soft Capsule combined with Donepezil,n=48)and control group(Donepezil alone,n=48)according to different treatment methods.Clinical efficacy after treatment,Montreal Cognitive Assessment(MoCA)scores,activities of daily living(ADL)scores,Unified Parkinson's Disease Rating Scale(UPDRS)scores,Mini-Mental State Scale(MMSE)scores,levels of recombinant human Parkinson disease protein 7(PARK7),neurotrophic factor-3(NT-3)and C-reactive protein(CRP)before and after treatment,and incidence rate of adverse reactions were compared between two groups.Results The total effective rate in research group was significantly higher than that in control group(P<0.01).After treatment,MoCA,ADL and MMSE scores were significantly higher,while UPDRS scores were significantly lower than those before treatment in two groups,and the changes were more obvious in research group than those in control group(P<0.05 or P<0.01).After treatment,NT-3,PARK7 and CRP levels were significantly improved compared with those before treatment in both groups,and the improvement conditions were more obvious in research group than those in control group(P<0.05 or P<0.01).The total incidence rate of adverse reactions in research group was significantly lower than that in control group(P<0.05).Conclusion Butylphthalide Soft Capsule combined with Donepezil in treatment of patients with Parkinson's syndrome may achieve good clinical efficacy,improve cognitive function and ADL of patients with good safety.
作者
薛静
张杰
高晓宇
韩云
XUE Jing;ZHANG Jie;GAO Xiao-yu;HAN Yun(Department of Neurology,People's Hospital of Liaoning Province,Shenyang 110016,China)
出处
《解放军医药杂志》
CAS
2021年第5期97-100,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
辽宁省自然科学基金指导计划(20170540512)。
关键词
帕金森障碍
丁苯酞软胶囊
多奈哌齐
认知功能
生活质量
药物毒性
Parkinsonian disorders
Butylphthalide soft capsules
Donepezil
Cognitive function
Quality of life
Drug toxicity
